作者
David A. Leiman,Harold S. Minkowitz,Roy C. Levitt,D. Solanki,D. Horn,David Janfaza,Dawn M. Sarno,N. Albores-Ibarra,X. Bai,Kenzo Takeshita,Tiefu Zhao,C. Lu,P. Bharathi,Jennifer Ahern,S. Klincewicz,Srdjan S. Nedeljkovic
摘要
Purpose: Osteoarthritis (OA) is a degenerative disease marked by breakdown of joint cartilage and associated bony changes. A dominant symptom is pain, which can become severe to the point where the patient is a candidate for joint replacement surgery. Although a wide range of analgesics and therapeutics are available, pain frequently remains an intractable problem. Even after total knee replacement, chronic knee pain has been reported in up to a third of patients. Resiniferatoxin (RTX) is a potent TRPV1 calcium channel agonist. RTX exposure results in prolonged calcium influx and ablation of TRPV1-positive nerve endings. In preclinical osteoarthritis models, RTX treatment leads to selective neurolysis of TRPV1-expressing pain sensory fibers and leaves sensory and motor neuron functions intact. We report on the preliminary safety and efficacy results from a phase 1B trial of resiniferatoxin administered intra-articularly as a one-time injection in subjects with moderate to severe pain due to knee osteoarthritis. Methods: In this multicenter, randomized, double-blind, placebo-controlled study, eligible subjects aged 35-85 years, with baseline pain score in the index knee of ≥5 but ≤9 (WOMAC pain subscale question A1) were treated with a one-time intra-articular dose of resiniferatoxin at escalating dose level cohorts of 5, 12.5, 20 and 30 mcg in 5 or 10 mL of saline, or saline placebo. For each 8-subject cohort the first subject received open-label RTX. Upon confirmation of safety in this sentinel subject, the remaining 7 subjects (5 RTX: 2 PBO) were enrolled in a blinded fashion. After confirmation of safety at each dose level by an independent DMC, the next higher dose level was opened for enrollment. Safety and efficacy data were collected over a twelve-week period. Subjects could be unblinded after a protocol-specified time period. Additional follow-up to 52 weeks was optional. Efficacy was assessed using the subject reported WOMAC and NPRS pain scores. Results: Enrollment of all planned dose escalation cohorts is complete, with 30 subjects receiving RTX and 10 receiving placebo. 70% are female and 30% are male. Median age is 62 years (range 44-83), and baseline WOMAC A1 score was mean 6.5 (S.D. 1.4). No dose-limiting toxicities were reported, and the maximum tolerated dose was not reached. The most frequently reported treatment-emergent adverse events were procedure-associated pain (post-procedural pain), which was reported in 80% of placebo subjects and in 100% of RTX subjects. This procedure-associated pain was reported as mild in severity in all placebo subjects, and mild in 73% and moderate in 27% of RTX subjects. Procedure-associated pain was managed with IV fentanyl, PO oxycodone, and other analgesics on the day of the injection. Typically, the pain subsided before being discharged that same day and subsided within 24 hours in all subjects. Other adverse events (reported in at least 2 RTX-treated subjects) were nausea (43%), vomiting and arthralgia (17%), hypertension and headache (10%) and hypoaesthesia (7%). Most events were mild, the few moderate events were of short duration; none were severe. There was no apparent relationship between adverse events and dose levels. In the secondary endpoint of efficacy, reduction in subject reported WOMAC A1 pain scores was observed at most dose levels. The difference in the mean score for WOMAC A1 (pain on walking on flat surface) at week 12 between the placebo subjects and RTX treated subjects expressed as the least squares mean difference (LSMD) in change from baseline relative to placebo, ranged from -0.04 to -2.63 points depending on the dose level cohort. By mixed model repeated measures (MMRM) analysis, the greatest pain reduction was observed at the 12.5 mcg dose (LSMD) versus placebo at 12 weeks of -2.63 by WOMAC A1 score (p = 0.0311, N=6) and -14.58 by WOMAC A pain index (p = 0.0134, N = 6). Compared to baseline pain by WOMAC A1, >70% reduction in the pain was achieved in 50% of pooled RTX-treated subjects and in 83% of the subjects at the 12.5 mcg dose. Pain reduction by RTX as assessed by the daily subject-reported NPRS pain scores were consistent with the WOMAC A1 data. Of the subjects dosed with RTX who have provided voluntary long-term follow-up, 3 of 4 subjects who have reached one year have maintained response. Conclusions: Resiniferatoxin demonstrated safety when given as one-time intra-articular injection up to the planned highest dose of 30 mcg. Preliminary efficacy was also observed. Anecdotal long-term follow up suggests sustained pain relief beyond Day 365. The clinical trial remains open to expansion cohorts to assess further the safety and efficacy at candidate doses to be implemented in future trials.